Intra-articular Injection of Lidocaine in Inflammatory Arthritis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-18

Study Completion Date

2022-10-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To assess the contributions of peripheral neurons to joint pain, the investigators plan to ask patients to rate the pain in their chosen joint before and after an injection of local anaesthetic (lidocaine) and steroid into their joint. Lidocaine blocks voltage gated sodium channels (VGSCs) leading to a reversible block of action potential propagation in peripheral nerves. If the pain intensity reduces significantly following lidocaine injection, it suggests that the patients' pain is due to peripheral sensitization, and that this is dampened by the local anaesthetic. If the pain intensity does not change or only falls slightly, then other centrally mediated factors are contributing to pain.

Before the investigators can use this method, the investigators need to ensure that reductions in pain score following joint injection are not due to placebo effect. Therefore, as part of this validation study patients will be randomised to receive either lidocaine plus steroid or, as a control, just steroid injection. The steroid is the main part of therapy as it relieves inflammation over a prolonged period, but is slower acting than lidocaine, and should not have an effect within ten minutes. Any improvement in ranking of pain within 10 minutes by patients receiving just steroid will therefore be due to placebo effect. The investigators hypothesis is that there will be a significant difference in change in pain score before and after injection between the study group (lidocaine plus steroid) and control group (0.9% saline plus steroid). This will confirm the absence of a significant placebo effect and mean the differences in change in pain scores seen in the study group are due to differences in pain processing

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Lidocaine and Neuroma Pain Related Modalities

NCT02300038

Neuropathic Pain

COMPLETED NA

Corticosteroid(CS) + Lido or Corticosteroid(CS) Alone

NCT03704584

Tenosynovitis

TERMINATED PHASE4

Cutaneous Administration of Local Anesthetic for Spine Injection Procedures

NCT00756301

Spinal Diseases

COMPLETED NA

Safety and Efficacy Study of an Iontophoretic Patch Containing Lidocaine and Epinephrine for Venipuncture in Healthy Adult Volunteers

NCT00889642

Local Anesthesia

COMPLETED PHASE2

Effect of Intravenous Lidocaine, Used to Attenuate Pain With Propofol Injection, on Defibrillation Threshold Testing

NCT03117166

Pain

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will be randomised to receive joint injection of either lidocaine plus steroid or, as a control, just steroid injection. Pain scores (visual analogue score 0-10) in the chosen joint will be collected prior to injection and at 3, 5 and 10 minutes post injection. Pain scores will then again be collected at 1 month and 3 months to determine whether lidocaine reduced peripheral pain long term.

Intra-articular joint injection with steroids is a frequent procedure in usual care and the investigators will only perform this test when a joint injection +/- aspiration is clinically indicated. Use of lidocaine in addition to steroid injection varies between rheumatologists, with 50% of Guys' and St Thomas' Hospital rheumatologists routinely using lidocaine and steroid, and others giving steroid alone. Therefore, all patients will still receive the same intervention they would if they were not taking part in the study, the only difference is measurement of pain scores before and after.

In addition to collection of pain scores, the investigators will collect patient demographics and painDETECT questionnaire, a screening questionnaire which has been validated to identify neuropathic elements of pain in patients with IA.

The investigators hypothesis is that there will be a significant difference in change in pain score before and after injection between the study group (lidocaine plus steroid) and control group (0.9% saline plus steroid). This will confirm the absence of a significant placebo effect and mean the differences in change in pain scores seen in the study group are due to differences in pain processing.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammatory Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Patients will be randomised to receive joint injection of either lidocaine plus steroid or, as a control, just steroid injection

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

SINGLE

Participants

Treatment allocation will be single blinded, in that the researcher will know what intervention the patient is receiving but the patient will not.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Lidocaine plus steroid

Group Type EXPERIMENTAL

depomedrone 40mg/ml + 1% lidocaine

Intervention Type DIAGNOSTIC_TEST

Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain

painDETECT questionnaire

Intervention Type OTHER

painDETECT questionnaire

Steroid only

Group Type PLACEBO_COMPARATOR

depomedrone 40mg/ml+ 0.9% saline

Intervention Type DIAGNOSTIC_TEST

Response to intra-articular injection of steroid only as a placebo

painDETECT questionnaire

Intervention Type OTHER

painDETECT questionnaire

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

depomedrone 40mg/ml + 1% lidocaine

Response to intra-articular injection of lidocaine as a diagnostic marker of peripheral pain

Intervention Type DIAGNOSTIC_TEST

depomedrone 40mg/ml+ 0.9% saline

Response to intra-articular injection of steroid only as a placebo

Intervention Type DIAGNOSTIC_TEST

painDETECT questionnaire

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of peripheral inflammatory joint disease
* Reporting current NRS pain ≥3 on a 0-10 scale
* Only perform this test when an aspiration and joint injection is clinically indicated and would be given as part of routine care

Exclusion Criteria

* Under 18 years of age
* Unable or unwilling to provide informed written consent
* Unable to comply with study protocols
* Pregnancy and breastfeeding
* If the chosen joint has been aspirated or injected in the preceding 3 months
* Presence of joint damage in chosen joint as assessed by Professor Kirkham on x-ray of the chosen joint (as joint damage itself can stimulate peripheral nociceptors)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No